The role of HIF-1α (Hypoxia-inducible factor 1 alpha) for the pathogenesis of psoriasis and related metabolic syndrome
The role of HIF-1α (Hypoxia-inducible factor 1 alpha) for the pathogenesis of psoriasis and related metabolic syndrome
批准号:
434262558
负责人:
Privatdozentin Dr. Natalie Garzorz-Stark, Ph.D.
金额:
$0.0万
依托单位国家:
德国
项目类别:
Research Fellowships
财政年份:
2019
资助国家:
德国
项目状态:
已结题
起止时间:
2018-12-31 至 2021-12-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Psoriasis is one of the most prevalent chronic inflammatory non-communicable skin diseases, affecting around 2% of the world's population. Patients not only suffer from itching, pain and social stigma, but also from associated comorbidities such as inflammatory bowel diseases and metabolic syndrome. Key signaling pathways and their cytokines have been decrypted and led to numerous symptomatic therapies. However, to develop preventive or causative therapeutic approaches, factors that lead to chronic disease and systemic involvement need to be identified. Our unpublished work gives clear hints that the transcription factor hypoxia-inducible factor 1 alpha (HIF-1α) is a checkpoint molecule for hallmarks of psoriasis pathogenesis as well as psoriasis-associated comorbidity, however, there is no direct evidence for this concept yet. I put up the hypothesis that after initiation of psoriatic inflammation leading to proliferation of keratinocytes and hypoxia in the epidermis, HIF-1α is activated leading to a) neoangiogenesis b) secretion of proinflammatory cytokines driving recruitment of neutrophils and systemic inflammation and c) a shift of T cell skin infiltrates towards Th17 phenotype, eventually creating the chronic psoriatic phenotype. In the course of this project I want to verify the above proposed hypothesis using histology, cell culture experiments, flow cytometry, murine knock-out models and clinical data from human data bases. The results of this project will increase our knowledge about the central molecular events leading to chronicity of psoriatic inflammation and thus lead to the development of novel drug targets. Collaborating with Professor Randall Johnson, leading a top lab in the field of hypoxia at the Karolinska Institute (KI) and working with Mona Ståhle, senior professor at the Division of Dermatology at KI, I will be able to perform this project in an ideal environment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
降脂消斑片通过HIF-1α/PKM2信号通路介导的能量代谢重编程抑制巨噬细胞铁死亡治疗动脉粥样硬化的作用机制
-
批准号:2026JJ60305
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:张杼惠
-
依托单位:
HIF-1α-FtL信号轴通过调控神经元铁稳态抑制NLRP3炎性小体活化在脑缺血再灌注损伤中的作用与机制研究
-
批准号:JCZRLH202600706
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
HIF1-α/PKM2调控糖酵解-STING组蛋白乳酸化介导小胶质细胞训练免疫在应激性认知功能障碍中的作用及机制
-
批准号:2026JJ50024
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:谭思杰
-
依托单位:
基于HIF-1α乳酸化修饰探讨桃红四物汤调控BMSCs-H型血管新生轴促进骨折愈合的分子机制研究
-
批准号:2026JJ80362
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:周新
-
依托单位:
HIF-1α介导H3K18乳酸化调控石榴皮多酚改善痤疮皮脂代谢紊乱机制研究
-
批准号:2026JJ60632
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:王云
-
依托单位:
糖尿病肾病肾纤维化改善新机制:SIRT3/HIF-1α维持足细胞脂代谢抑制细胞焦亡
-
批准号:2026JJ82303
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:刘润芝
-
依托单位:
miR-30c-5p通过MTDH/HIF-1α/PKM2环形反馈抑制乳腺癌进展的作用及机制研究
-
批准号:JCZRLH202600025
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
肿瘤相关成纤维细胞通过分泌COL10A1 介导HIF1α/KLF5调控肝细胞癌上皮间质转化和血管生成拟态的机制研究
-
批准号:JCZRLH202602031
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
基于HIF-1αVEGFMMPs信号通路研究经筋弹拨法改善KOA大鼠骨破坏的研究
-
批准号:2026JJ80645
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:胡金鲁
-
依托单位:
金黄跌打散联合海桐皮汤通过HIF-1α/VEGF通路干预新生血管形成防治软骨损伤的机制研究
-
批准号:2026JJ81074
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:钟炜钰
-
依托单位: